Table 1.
Variables associated with antibody response after SARS-COV-2 vaccination in patients with solid tumor (n = 171) and hematologic diseases (n = 107). Multivariate linear regression model included completion of vaccination scheme, day of Antibody testing after first vaccine and oncological treatment (ongoing vs. observation-only) and was corrected for sex and age.
| Patient Groups | Factors | Unstandardized Coefficients Beta | 95.0% CI | p-Value | Adjusted R2 | F Value | |
|---|---|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||||
| Vaccinated solid tumor patients | Sex | 20.352 | −3.252 | 43.957 | 0.091 | 0.53 | 39.9 |
| Age | −1.561 | −2.569 | −0.552 | 0.003 | - | - | |
| Completion of vaccination scheme | 170.454 | 138.855 | 202.054 | 0.000 | - | - | |
| Day of Ab testing after first vaccine | 0.453 | −0.189 | 1.094 | 0.165 | - | - | |
| Ongoing oncological treatment | −26.922 | −56.133 | 2.289 | 0.071 | - | - | |
| Vaccinated hematologic patients | Sex | 26.870 | 15.420 | 69.159 | 0.210 | 0.13 | 4.2 |
| Age | −1.328 | −2.826 | 0.169 | 0.082 | - | - | |
| Completion of vaccination scheme | 106.050 | 48.891 | 163.209 | 0.000 | - | - | |
| Day of Ab testing after first vaccine | −0.140 | −1.264 | 0.984 | 0.805 | - | - | |
| Ongoing hematological treatment | 31.434 | 75.663 | 12.796 | 0.162 | - | - | |
Significant p-values are displayed bold. Ab: Antibody; CI: Confidence Interval.